Home > Insider Trading > Filing (0001209191-18-034644)

Filing Details

Accession Number:: 0001209191-18-034644
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-06-01 16:08:10
Reporting Period:: 2018-05-30

Accepted Time:: 2018-06-01 16:08:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc	AGIO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1578200	P David Schenkein	C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-05-30	5,962	$0.30	5,962	No	4	M	Direct
Common Stock	Acquisiton	2018-05-30	16,193	$0.30	22,155	No	4	M	Direct
Common Stock	Acquisiton	2018-05-30	23,471	$0.47	45,626	No	4	M	Direct
Common Stock	Disposition	2018-05-30	45,626	$90.07	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2018-05-30	5,962	$0.00	5,962	$0.30
Common Stock	Stock option (right to buy)	Disposition	2018-05-30	16,193	$0.00	16,193	$0.30
Common Stock	Stock option (right to buy)	Disposition	2018-05-30	23,471	$0.00	23,471	$0.47

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2019-08-12	No	4	M	Direct
0	2019-08-12	No	4	M	Direct
12,892	2021-03-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	271,772	Indirect	See footnote
Common Stock	79,082	Indirect	See footnote

Footnotes

This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $90.00 to $90.63. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
This option was granted on August 13, 2009. The shares underlying this option vested as to 25% of the shares on August 1, 2010, and the remaining 75% vested in 36 equal monthly installments thereafter.
This option was granted on August 13, 2009. The shares underlying this option vested as to 50% upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and the remaining 50% of the underlying shares vested in equal monthly installments through June 3, 2013.
This option was granted on March 2, 2011. The shares underlying this option vested as to 25% of the shares on the date of grant and as to 25% of the shares upon the achievement of a performance milestone on July 19, 2013. The remaining 50% of the shares underlying the option vested in equal monthly installments through July 19, 2015.